You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 6,979,296

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,979,296

Title:	Methods for ultrasonic imaging and treating diseased tissues
Abstract:	A method for imaging diseased tissue is provided. The method provides delivering to the diseased tissue a liposomal imaging agent comprising liposomes containing an imaging agent. The liposomal imaging agent is bound to an antibody by an antigenic linker so that the antibody binds the liposomal imaging agent to the diseased tissue. The liposomes are broken to release the imaging agent using a catheter, and the imaging agent is viewed using an imaging technique. The tissue can also be treated by delivering a therapeutic agent to the tissue using the catheter, for example, within the liposomes of the liposomal imaging agent.
Inventor(s):	See; Jacko R. (Fullerton, CA)
Assignee:		SBM Biologics, Inc. (Cupertino, CA)
Application Number:	10/406,748
Patent Claims:	1. A method for imaging diseased tissue, comprising: delivering to the diseased tissue a liposomal imaging agent comprising liposomes containing an imaging agent, the liposomal imaging agent being bound to an antibody by an antigenic linker, wherein the antibody binds the liposomal imaging agent to the diseased tissue; breaking the liposomes to release the imaging agent using a catheter; and viewing the imaging agent using an imaging technique. 2. The method according to claim 1, wherein the liposomal imaging agent is delivered to the diseased tissue using the catheter. 3. The method according to claim 1, wherein the liposomes are broken by applying radio frequency energy or ultrasound energy with the catheter. 4. The method according to claim 1, wherein the antibody is selected from the group consisting of polyclonal antibodies, monoclonal antibodies, cytokines, growth factors, immunoglobulin, matrix metalloproteases, amino acids, peptides, extracellular matrix proteins, purified neurochemicals, chemokines, RNA fragments, DNA fragments, and nucleic acids. 5. The method according to claim 1, wherein the liposomal imaging agent comprises gas-filled liposomes. 6. The method according to claim 5, wherein the gas-filled liposomes comprise at least one gas selected from the group consisting of air, oxygen, hydrogen, nitrogen, fluorocarbons, argon, xenon, helium, and fluoropropanes. 7. The method according to claim 5, wherein the gas-filled liposomes are prepared by: preparing liposomes comprising an inner retentate surrounded by one or more outer layers; freezing and thawing the liquid liposomes to induce the inner retentate to go directly from the solid state to the gaseous state while the one or more outer layers of the liposome do not. 8. The method according to claim 1, further comprising delivering energy directly into the diseased tissue using the catheter. 9. The method according to claim 8, wherein the energy is selected from radio frequency energy and ultrasound energy. 10. The method according to claim 1, further comprising, after viewing the imaging agent, breaking the antigenic linkage using the catheter to release the liposomes from the diseased tissue. 11. A method for imaging and treating diseased tissue comprising: imaging diseased tissue according to the method of claim 1, wherein the liposomes containing the imaging agent further contain a therapeutic agent; and breaking the liposomes to release the therapeutic agent to thereby treat the diseased tissue with the therapeutic agent. 12. The method according to claim 11, wherein the therapeutic agent is selected from the group consisting of trastuzumab, infliximab and abciximab. 13. A method for imaging and treating diseased tissue comprising: imaging diseased tissue according to the method of claim 1; and introducing a therapeutic agent to the diseased tissue using the catheter to thereby treat the diseased tissue. 14. The method according to claim 13, wherein the therapeutic agent is selected from the group consisting of trastuzumab, infliximab and abciximab. 15. The method according to claim 13, wherein the therapeutic agent is contained within liposomes. 16. The method according to claim 1, wherein the diseased tissue is selected from the group consisting of tumors, areas of infection, areas of infarction, areas of scarring, areas of degeneration, and areas of tissue overgrowth of unknown etiology.

Details for Patent 6,979,296

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994	⤷ Try a Trial	2022-04-03
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2022-04-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2022-04-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2022-04-03
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2022-04-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.